TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Amplia Therapeutics ( (AU:ATX) ) has shared an announcement.
Amplia Therapeutics has commenced trading on the U.S. OTCQB Venture Market, enhancing its engagement with U.S. investors and expanding its presence in the U.S. market. This move coincides with the company’s AMPLICITY clinical trial for advanced pancreatic cancer opening at five sites in the U.S., and is part of Amplia’s broader strategy to educate investors about its FAK inhibitor program, which includes the promising drug narmafotinib.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company targets fibrotic cancers such as pancreatic and ovarian cancer, and FAK is also significant in chronic diseases like idiopathic pulmonary fibrosis.
Average Trading Volume: 2,681,963
Technical Sentiment Signal: Sell
Current Market Cap: A$64.13M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.